ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

FTC Seeks Additional Info From Teva, Cephalon Regarding Merger

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and acquisition target Cephalon Inc. (CEPH) each received a request to provide additional information to the U.S. Federal Trade Commission related to a pending $6.8 billion deal between the firms. Israel-based Teva, which trumped a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) in agreeing to buy Cephalon last month, said it had expected the request. The parties have been cooperating with the FTC staff since shortly after the bid was announced, according to Teva, which said it intends to win clearance "as promptly as possible." Teva on Monday said it continues to expect the deal to be completed in the third quarter, following clearance from U.S. and European regulators, as well as winning approval of Cephalon shareholders. Teva's American depositary shares were recently up 0.4% to $49.35 in after-hours trading. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
02/09/201610:55:33Amended Statement of Ownership (sc 13g/a)
02/09/201601:00:00Pharming and Cytobioteck Announce Extension of Distribution Agreement...
02/05/201617:06:17Amended Statement of Beneficial Ownership (sc 13d/a)
02/04/201612:57:00Martin Shkreli Takes the Fifth Before Congress--3rd Update
02/04/201611:23:00Martin Shkreli Takes the Fifth Before Congress--2nd Update
02/04/201611:13:00Martin Shkreli Takes the Fifth Before Congress--Update
02/04/201611:00:00Martin Shkreli Takes the Fifth Before Congress
02/04/201610:50:00Martin Shkreli Takes the Fifth Before Congress
02/03/201618:49:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:30:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/03/201618:19:00Valeant's Interim CEO to Seek Change to Rules for Prescription...
02/02/201620:12:00Correction to Companies Boosted Drug Prices To Fuel Preset Profits
02/02/201617:30:17Current Report Filing (8-k)
02/02/201616:20:00Valeant, Turing Boosted Drug Prices To Fuel Preset Profits
01/28/201616:12:26Statement of Changes in Beneficial Ownership (4)
01/25/201608:48:00Valeant's Pearson: 'On the Road to Recovery' -- 2nd Update
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201608:00:00Valeant Announces FDA Acceptance of BLA Submission for Brodalumab...
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson
01/25/201607:00:00Valeant Provides Update On J. Michael Pearson

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad